Competitor Landscape: HIV
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Doravirine (approved in the US in Aug 2018) provides a tolerable NNRTI option with a high barrier to resistance, and is expected be used as part of multi-pill triple combinations where it may replace older NNRTIs
If approved, ibalizumab would be the first biologic and first long-acting HIV drug in the EU, and would provide an option for patients with multidrug-resistant HIV infection which represents a population with a high unmet need
While Frontier Biotech received China approval for albuvirtide for the treatment of HIV in Jun 2018, its FDA approved IND for a Phase II trial of albuvirtide + 3BNC117 is the first indication of clinical activity in the US
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Aphios
Argos Therapeutics
Bionor
Biotron
Bristol-Myers Squibb
CSL Behring
CytoDyn
EnzoBiochem
FIT Biotech
Frontier Biotech
Gilead
GlaxoSmithKline
ID Pharma
Immune Response BioPharma
Immune System Regulation
InnaVirVax
Inovio
Janssen
Kanglin Biotech
MacroGenics
Merck & Co
Mologen
PaxVax
Sangamo
Sumagen
TaiMed Biologics
Takeda
Theravectys
Tobira
United BioPharma
ViiV
Viriom
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.